Rheum Manpower Needs - More Programs! (12.2.2022)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Biologics in Lupus – Why, Who, and When? Sponsored by GSK US Medical Affairs

Save

Leading experts from the SLE Educators’ Network discuss how biologic therapies may help address key unmet needs in lupus, while highlighting how clinicians can identify the most appropriate patients for biologic treatment.

Topic Podcasts - JAK TYK2

Save

ACR22 Year in Review Report Deucravacitinib in PsA JAK inhibitors in rheumatic diseases JAK vs TNF inhibitor Infections in RA New Treatments for SLE? Prelude to a Meeting (ACR22) (11.11.2022) Switching Between JAK Inhibiters in RA Tapering Methotrexate with Biologics or JAK Inhibitors in RA Tofacitinib and RA-ILD Upadacitinib vs Adalimumab in PsA u

Topic Podcasts - Lupus Part3

Save

Addressing Sexual Health and STD Prevention in Lupus Patients CAR-T Therapies in Antiphospholipid Antibody Syndrome Copays Reduce Adherence to SLE Medications Diffuse alveolar hemorrhage in antiphospholipid syndrome Hydroxychloroquine Update from ACR22 Low-grade Proteinuria in Non Renal Lupus: Should We be Worried? Photovoice: A New Visual Research

Topic Podcasts - Lupus Part2

Save

ACR22 Daily Recap: Saturday Recap New Treatments for SLE?

Topic Podcasts - Lupus Part1

Save

A Novel Treatment Response Measurement Tool for Lupus ACR22 Year in Review Report Breakthrough COVID infection in SLE during Omicron era Effect of voclosporin in class V lupus nephritis Lupus, Sex and STDs Poor Medication Adherence in SLE and How to Improve It Prelude to a Meeting (ACR22) (11.11.2022) Should You Repeat the ENA Panel? Urinary Biomar

Topic Podcasts - PsA Part3

Save

Sunday (Day 2): ACR 22 Daily Recap

Topic Podcasts - PsA Part2

Save

ACR 2022 Appraisal, Praise & Critique (11.18.2022) Best of ACR Day Two in PSA Efficacy and Safety Results from BE OPTIMAL in PsA JAK inhibitors in rheumatic diseases Oligoarticular PsA: FOREMOST Study Opioid use in PsA and SpA PET CT Imaging to Define Risk of Progression from PSO to PsA PsA and SPA: Cyclers, Switchers, Who is the Winner? Switch

Topic Podcasts - PsA Part1

Save

Best of PsA on Day 1 Can computers tell the difference between RA & PsA? Deucravacitinib in PsA Differences in Presentation and Outcomes of Early vs Late Onset PsA Opioids and Health Care Utilization in PsA and AS Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor PsA Cycling or Switching MOAs The Dietary Intervention in PsA (DIPSA)

Topic Podcasts - RA Part4

Save

Sunday (Day 2): ACR 22 Daily Recap

Topic Podcasts - RA Part3

Save

Bouncebackability portends increased risk of adverse outcomes in RA Can I stop Methotrexate in RA? Fat and bone are never alone: osteoporotic fracture in RA JAK inhibitors in rheumatic diseases RA: Steroids are bad, again Reproductive health in a post-Roe world Sensor-engineered glove evaluates hand function in RA Tapering Methotrexate with Biologi

Topic Podcasts - RA Part2

Save

ACR22 Daily Recap: Saturday Recap JAK vs TNF inhibitor Infections in RA Opioid and Neuropathic Use After Initiating btsDMARDs in RA Pre-RA Pharmacological Interventions: Delaying is not Enough PreRA to Treat or Not! Prescribing Methotrexate in Post-Roe Era The Great Debate: To Treat or Not to Treat Pre RA To Switch or Not: Biosimilars in Inflammato